Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Treatment of atrial fibrillation with embolization,Prophylaxis and treatment of peripheral arterial embolism,Anticoagulant use in extracorporeal circulation (e.g., during hemodialysis, cardiopulmonary bypass),Unstable angina and non-ST-segment elevation myocardial infarction (off-label),Acute coronary syndromes (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on a PTT. Typical maintenance: 1300 units/hour for adult (70 kg).
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Mean 1-2 hours (dose-dependent: increases with dose due to saturable clearance; at 100 U/kg IV: ~1 hr; at 400 U/kg: ~2.5 hrs); clinical context: may be prolonged in hepatic/renal disease
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Heparin is metabolized by the liver and reticuloendothelial system. It is partially desulfated and depolymerized; some components are excreted unchanged in urine. Metabolism is dose-dependent and saturable at high doses.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal (primarily via saturable mechanism; small amount metabolized by liver and reticuloendothelial system; no biliary/fecal elimination of significance)
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Very high, ~95-98% (binds to antithrombin III, albumin, and other plasma proteins)
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.05-0.1 L/kg (confined to plasma volume; low Vd due to high protein binding and large molecular size)
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
SC: 20-30% (variable based on injection site and depth); IV: 100%
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific GFR-based dose adjustment required; monitor a PTT and adjust accordingly. Accumulation not significant due to large molecular weight and extensive protein binding.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific Child-Pugh based modifications. Heparin clearance may be reduced in severe hepatic impairment; monitor coagulation parameters closely.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
IV: Bolus 75-100 units/kg over 10 minutes, then continuous infusion: Infants: 28 units/kg/hour; Children >1 year: 20 units/kg/hour; Adolescents: 18 units/kg/hour. Titrate to target a PTT (usually 60-85 seconds).
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients (≥65 years) may have reduced heparin clearance; use lower initial infusion rates (e.g., 15 units/kg/hour) and monitor a PTT frequently to avoid over-anticoagulation.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Heparin is not intended for intramuscular use. There is an increased risk of bleeding complications. Monitor platelet counts regularly; heparin-induced thrombocytopenia (HIT) can occur. Use with caution in patients with history of HIT. Preservative-free heparin should be used in neonates and infants.
None.
Monitor for signs of bleeding (hematuria, melena, easy bruising, epistaxis, etc.),Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS): discontinue heparin immediately if HIT suspected,Epidural or spinal catheter use: risk of spinal or epidural hematoma with concurrent anticoagulants,Hyperkalemia due to aldosterone suppression (especially in elderly, diabetic, renally impaired),Osteoporosis with prolonged use (>1 month),Hypersensitivity reactions including urticaria, angioedema, anaphylaxis
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to heparin or any component,History of heparin-induced thrombocytopenia (HIT) or HITTS,Active major bleeding (e.g., GI bleeding, intracranial hemorrhage),Severe thrombocytopenia (platelet count <100,000/mm³),Use of intramuscular injections while on heparin,Uncontrollable bleeding diathesis (e.g., hemophilia, severe liver disease)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. However, avoid excessive intake of foods high in vitamin K (e.g., leafy green vegetables, broccoli, Brussels sprouts) unless consistent consumption pattern is maintained, as vitamin K can antagonize heparin's effect indirectly. Alcohol may increase bleeding risk and should be limited.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Heparin is not excreted into breast milk due to high molecular weight. Compatible with breastfeeding. M/P ratio not applicable (not measurable).
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require higher doses to achieve therapeutic a PTT. Dose adjustment based on a PTT monitoring advised.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Heparin sodium 10,000 units in 0.45% sodium chloride is a high-concentration infusion typically used for continuous intravenous administration in acute thrombotic events or prophylaxis. Confirm compatibility with all IV lines and medications; avoid concurrent use with other anticoagulants without clear indication. Monitor a PTT closely, targeting 1.5-2.5 times control for therapeutic effect. Rapid reversal requires protamine sulfate (1 mg per 100 units heparin). Use with caution in renal impairment, elderly, and patients with history of heparin-induced thrombocytopenia (HIT). Check platelet counts every 2-3 days to detect HIT early. Weight-based dosing is standard; this formulation is often used for bolus administration or infusion in fluid-restricted patients.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
You will receive this medication through an IV line to prevent or treat blood clots.,You may experience bruising or bleeding more easily; report any unusual bleeding, dark stools, or blood in urine immediately.,Avoid taking aspirin, ibuprofen, or other NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Inform all healthcare providers (including dentists) that you are taking heparin.,Do not discontinue the medication suddenly; it will be tapered as directed by your doctor.,You may be required to have regular blood tests (a PTT, platelet count) to monitor the drug's effect.,Notify your doctor immediately if you develop chest pain, shortness of breath, or signs of allergic reaction (rash, difficulty breathing).
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is: IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on a PTT. Typical maintenance: 1300 units/hour for adult (70 kg).. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is classified as Category A/B. Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.